Clerson P, Carre A, Berthet P, Deltour L, Billaut P, Debeaumont D, Tarrade T, Lefebvre J
AMPLSW, Wattrelos.
Arch Mal Coeur Vaiss. 1989 Nov;82 Spec No 4:139-43.
The effects of cicletanine hydrochloride on glucose tolerance parameters were studied in a two-phase trial in which patients received a placebo for 2 weeks, followed by cicletanine 50 mg/day for 3 months. Ten patients with mild to moderate hypertension, who were neither obese nor diabetic and had no disorder of glucose tolerance entered the study. None of the patients was withdrawn. Glucose tolerance was evaluated by two oral glucose tolerance tests performed at 90 days' interval, each with half hourly blood glucose and insulin assays. The clinical effectiveness of the drug was assessed by monthly blood pressure measurements. No significant change in glycaemia and insulinaemia was observed. There was a significant decrease of supine SBP from 170.7 +/- 9.1 mmHg to 150.3 +/- 6.7 mmHg (p less than 0.0001) and of supine DBP from 101.3 +/- 4.1 to 80.3 +/- 7.7 mmHg (p less than 0.0001). At the end of the study, 9 of the 10 patients had normal blood pressure values. No undesirable clinical or biochemical effect was noted. thus, cicletanine, an antihypertensive drug derived from furopyridine, proved to be devoid of adverse effects on glycoregulation and clinically effective on hypertension.
在一项两阶段试验中研究了盐酸西氯他宁对糖耐量参数的影响，在该试验中，患者先接受2周的安慰剂治疗，随后接受50毫克/天的西氯他宁治疗3个月。10名轻度至中度高血压患者进入该研究，这些患者既不肥胖也无糖尿病，且糖耐量正常。没有患者退出研究。通过每隔90天进行两次口服葡萄糖耐量试验评估糖耐量，每次试验均每半小时测定血糖和胰岛素。通过每月测量血压评估药物的临床疗效。未观察到血糖和胰岛素血症有显著变化。仰卧位收缩压从170.7±9.1毫米汞柱显著降至150.3±6.7毫米汞柱（p<0.0001），仰卧位舒张压从101.3±4.1降至80.3±7.7毫米汞柱（p<0.0001）。研究结束时，10名患者中有9名血压值正常。未观察到不良临床或生化效应。因此，源自呋吡啶的抗高血压药物西氯他宁被证明对糖调节无不良影响，且对高血压有临床疗效。
